Royalty Pharma PLC RPRX
We take great care to ensure that the data presented and summarized in this overview for Royalty Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPRX
View all-
Morgan Stanley New York, NY46.6MShares$1.67 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA36.4MShares$1.3 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$825 Million0.01% of portfolio
-
Capital International Investors Los Angeles, CA21.9MShares$785 Million0.14% of portfolio
-
Baillie Gifford & CO18MShares$646 Million0.51% of portfolio
-
Swedbank Ab Stockholm, V712.2MShares$436 Million0.51% of portfolio
-
State Street Corp Boston, MA10.2MShares$366 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA8.18MShares$293 Million0.02% of portfolio
-
Caledonia (Private) Investments Pty LTD Sydney Nsw, C36.44MShares$231 Million5.9% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6MShares$215 Million0.38% of portfolio
Latest Institutional Activity in RPRX
Top Purchases
Top Sells
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Insider Transactions at RPRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 11
2025
|
Gregory Norden Director |
SELL
Open market or private sale
|
Direct |
33,500
-14.67%
|
$1,206,000
$36.23 P/Share
|
Aug 08
2025
|
Gregory Norden Director |
BUY
Conversion of derivative security
|
Direct |
144,660
+38.78%
|
-
|
Aug 06
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
21,901
+2.36%
|
-
|
Aug 06
2025
|
Christopher Hite EVP & Vice Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
3,696
+0.56%
|
-
|
Aug 06
2025
|
George W. Lloyd EVP, Investments & CLO |
BUY
Grant, award, or other acquisition
|
Indirect |
3,696
+6.6%
|
-
|
Aug 06
2025
|
Terrance P. Coyne EVP & CFO |
BUY
Grant, award, or other acquisition
|
Indirect |
3,696
+6.6%
|
-
|
Aug 06
2025
|
Marshall Urist EVP, Research & Investments |
BUY
Grant, award, or other acquisition
|
Direct |
2,772
+6.6%
|
-
|
Jul 31
2025
|
Elizabeth H Weatherman Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,558
+45.21%
|
-
|
Jul 31
2025
|
Carole Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,558
+45.21%
|
-
|
Jun 30
2025
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,064
+1.6%
|
$37,240
$35.24 P/Share
|
Jun 30
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,064
+1.47%
|
$37,240
$35.24 P/Share
|
May 16
2025
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Other acquisition or disposition
|
Direct |
530,348
+37.54%
|
-
|
May 13
2025
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+12.96%
|
-
|
May 13
2025
|
David C Hodgson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+18.6%
|
-
|
May 13
2025
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+12.39%
|
-
|
May 13
2025
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+8.34%
|
-
|
May 13
2025
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+9.8%
|
-
|
May 13
2025
|
Vlad Coric Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+41.35%
|
-
|
May 13
2025
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+8.56%
|
-
|
May 13
2025
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,614
+10.59%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 598K shares |
---|---|
Other acquisition or disposition | 530K shares |
Conversion of derivative security | 445K shares |
Open market or private sale | 33.5K shares |
---|